Xeris Pharmaceuticals Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Chicago, IL USA
Total Funding:$237.6M
Industry:Pharma
Founded:N/A
Lead Investor(s):Merieux Développement
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Xeris Pharmaceuticals's estimated annual revenue is currently $2.5M per year.
  • Xeris Pharmaceuticals received $10.0M in venture funding in March 2018.
  • Xeris Pharmaceuticals's estimated revenue per employee is $14,006
  • Xeris Pharmaceuticals's total funding is $237.6M.

Employee Data

  • Xeris Pharmaceuticals has 176 Employees.
  • Xeris Pharmaceuticals grew their employee count by 47% last year.
  • Xeris Pharmaceuticals currently has 3 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Kalderos
$6.8M34240%N/A
Raland Complian...
$10.5M5224%N/A
GCE Solutions
$26M38019%N/A
MedLogix Commun...
$3.4M17N/AN/A
Regis Technolog...
$20.1M100-12%N/A
Precision Dose
$9.4M472%N/A
Nexus Pharmaceu...
$12.1M6043%N/A
Care One Pharma...
$8.4M4224%N/A
Fluid Air
$10.3M5128%N/A
Firma Clinical ...
$16.7M830%N/A
Missing a competitor? Contribute!?
Submit

Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company's proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Solar Power

176

Number of Employees

$2.5M

Revenue (est)

3

Current Jobs

47%

Employee Growth %

$237.6M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Paul EdickChairman And Ceo
John ShannonChief Operating Officer
Allison WeySenior Vice President, Investor Relations & Corporate Communications
Ed DrowerDirector Quality
Mike DavisDirector, Quality Control
Chelsea BoundySenior Manager, Regulatory Operations
Aziz AlamSenior Director, Global Regulatory Affairs
Ashley GregoryCorporate Training Manager
John T. MathisRegional Medical Affairs DirectorEmail Available
Rondell WillsTerritory Business Manager

Xeris Pharmaceuticals News

09/05/2019 - Xeris: Preparing For The Gvoke PDUFA

After a three-month PDUFA extension, Xeris Pharmaceuticals and XERS investors are preparing for Gvoke's new PDUFA date on September ...

09/04/2019 - Have Insiders Been Buying Xeris Pharmaceuticals, Inc ...

So shareholders might well want to know whether insiders have been buying or selling shares in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS).

09/06/2019 - Xeris Pharma's Gvoke: Strong Approval Chances, But This Is ...

Xeris Pharma's Gvoke is a stable and ready to use glucagon self-injector therapy. It has shown non-inferiority to Lilly and Novo Nordisk ...

Xeris Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2011-12-13$1.5MACentral Texas Angel NetworkArticle
2013-07-15$2.3MUndisclosedMultipleArticle
2015-01-09$17.9MUndisclosedArticle
2016-01-08$41.0MCRedmile GroupArticle
2017-05-19$30.0MCRedmile GroupArticle
2018-03-09$45.0MUndisclosedSilicon Valley BankArticle
2018-03-09$10.0MCMerieux DéveloppementArticle

Xeris Pharmaceuticals Executive Hires

DateNameTitleReference
2015-01-09Phillip JohnsonCFOArticle